BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

Published: 8-Dec-2023
Research & Development

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects

BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
 
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.

See more

You may also like

Research & Development
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

Read more
The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif

Trending Articles

  1. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  2. Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
  3. FDA Form 483 explained: responding to findings and managing regulatory risk Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes
  4. ADC development demands a new level of bioconjugation expertise Why growing ADC complexity is placing greater demands on bioconjugation and manufacturing expertise
  5. Making blister package integrity testing decisions that QA can use A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions

You may also like

Research & Development
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
Research & Development
Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments
Manufacturing
Making blister package integrity testing decisions that QA can use

Making blister package integrity testing decisions that QA can use

A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions
Manufacturing
FDA inspection readiness: Preparing for surveillance and pre-approval inspections

FDA inspection readiness: Preparing for surveillance and pre-approval inspections

Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
Manufacturing
ADC development demands a new level of bioconjugation expertise

ADC development demands a new level of bioconjugation expertise

Why growing ADC complexity is placing greater demands on bioconjugation and manufacturing expertise
Manufacturing
FDA Form 483 explained: responding to findings and managing regulatory risk

FDA Form 483 explained: responding to findings and managing regulatory risk

Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes
Regulatory
Leica Biosystems brings Tempus pathology products to Aperio AI Store

Leica Biosystems brings Tempus pathology products to Aperio AI Store

Expanding the Aperio AI Store gives researchers more ways to study cancer through AI-enabled tools within a connected digital pathology ecosystem
Subscribe now